
4WEB Medical was granted 510(k) clearance to market its sacroiliac (SI) Joint Truss System, indicated for fusion of the SI joint for SI joint dysfunction including SI joint disruption and degenerative sacroiliitis.
The product consists of two initial designs: one, a fully threaded SI fusion device, and a second design incorporating a lag feature. Each configuration will be provided in three diameters with varying lengths to accommodate the patient’s anatomy.
Jessee Hunt, Founder and CEO of 4WEB commented, “With years of research and development around Truss Implant Technology, our most recent study out of UPENN McKay Orthopaedic Research Laboratory demonstrates that the truss architecture converts physiologic load into therapeutic strain at the surgical site, amplifying osteogenic activity. This therapeutic effect provides ongoing support while biologic fusion takes place.”
Source: 4WEB Medical
4WEB Medical was granted 510(k) clearance to market its sacroiliac (SI) Joint Truss System, indicated for fusion of the SI joint for SI joint dysfunction including SI joint disruption and degenerative sacroiliitis.
The product consists of two initial designs: one, a fully threaded SI fusion device, and a second design incorporating a lag...
4WEB Medical was granted 510(k) clearance to market its sacroiliac (SI) Joint Truss System, indicated for fusion of the SI joint for SI joint dysfunction including SI joint disruption and degenerative sacroiliitis.
The product consists of two initial designs: one, a fully threaded SI fusion device, and a second design incorporating a lag feature. Each configuration will be provided in three diameters with varying lengths to accommodate the patient’s anatomy.
Jessee Hunt, Founder and CEO of 4WEB commented, “With years of research and development around Truss Implant Technology, our most recent study out of UPENN McKay Orthopaedic Research Laboratory demonstrates that the truss architecture converts physiologic load into therapeutic strain at the surgical site, amplifying osteogenic activity. This therapeutic effect provides ongoing support while biologic fusion takes place.”
Source: 4WEB Medical
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





